Globus Medical Inc (GMED) Receives Average Recommendation of “Hold” from Brokerages

Shares of Globus Medical Inc (NYSE:GMED) have received a consensus rating of “Hold” from the fourteen ratings firms that are currently covering the company. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $25.00.

Several research firms have issued reports on GMED. Canaccord Genuity reiterated a “hold” rating and set a $27.00 target price on shares of Globus Medical in a research report on Monday, January 23rd. Zacks Investment Research upgraded Globus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, January 10th. Aegis began coverage on Globus Medical in a research report on Wednesday, November 30th. They set a “buy” rating and a $31.00 target price on the stock. Leerink Swann reiterated a “hold” rating and set a $23.00 target price on shares of Globus Medical in a research report on Wednesday, November 9th. Finally, Oppenheimer Holdings, Inc. cut Globus Medical from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $29.00 to $23.00 in a research report on Wednesday, November 9th.

This story was first published by Zolmax and is the property of of Zolmax. If you are accessing this story on another domain, it was copied illegally and republished in violation of United States & international copyright law. The legal version of this story can be read at https://zolmax.com/investing/globus-medical-inc-gmed-receives-average-recommendation-of-hold-from-brokerages/1208630.html.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/globus-medical-inc-gmed-receives-average-recommendation-of-hold-from-brokerages/1208630.html

Several large investors have recently added to or reduced their stakes in GMED. Eagle Asset Management Inc. boosted its stake in Globus Medical by 13.8% in the third quarter. Eagle Asset Management Inc. now owns 165,298 shares of the medical device company’s stock worth $3,730,000 after buying an additional 20,055 shares in the last quarter. Capital Impact Advisors LLC boosted its stake in Globus Medical by 61.3% in the third quarter. Capital Impact Advisors LLC now owns 63,926 shares of the medical device company’s stock worth $1,443,000 after buying an additional 24,300 shares in the last quarter. Royal Bank of Canada boosted its stake in Globus Medical by 17.0% in the second quarter. Royal Bank of Canada now owns 308,444 shares of the medical device company’s stock worth $7,350,000 after buying an additional 44,924 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Globus Medical by 2.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 257,876 shares of the medical device company’s stock worth $6,146,000 after buying an additional 5,388 shares in the last quarter. Finally, Fiera Capital Corp boosted its stake in Globus Medical by 359.0% in the second quarter. Fiera Capital Corp now owns 373,623 shares of the medical device company’s stock worth $8,904,000 after buying an additional 292,223 shares in the last quarter. Institutional investors and hedge funds own 88.55% of the company’s stock.

Shares of Globus Medical (NYSE:GMED) traded up 0.70% during trading on Friday, reaching $27.46. The company had a trading volume of 252,943 shares. The firm’s 50 day moving average price is $26.13 and its 200 day moving average price is $23.60. The firm has a market capitalization of $2.63 billion, a P/E ratio of 22.51 and a beta of 0.63. Globus Medical has a 12 month low of $19.25 and a 12 month high of $27.66.

Globus Medical Company Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

5 Day Chart for NYSE:GMED

Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Superior Energy Services, Inc.  Research Coverage Started at Tudor Pickering
Superior Energy Services, Inc. Research Coverage Started at Tudor Pickering
TELE2 AB  Stock Rating Upgraded by Zacks Investment Research
TELE2 AB Stock Rating Upgraded by Zacks Investment Research
UCB  Upgraded at Zacks Investment Research
UCB Upgraded at Zacks Investment Research
Morgan Stanley Increases Childrens Place Inc  Price Target to $140.00
Morgan Stanley Increases Childrens Place Inc Price Target to $140.00
Secure Income REIT PLC  Earns Buy Rating from Goldman Sachs Group Inc
Secure Income REIT PLC Earns Buy Rating from Goldman Sachs Group Inc
CME Group Inc  Receives $102.95 Consensus Target Price from Brokerages
CME Group Inc Receives $102.95 Consensus Target Price from Brokerages


Leave a Reply

 
© 2006-2017 Zolmax.